Skip to main content
Premium Trial:

Request an Annual Quote

Dako, Bristol-Myers Ink Pharmacogenomics Deal

NEW YORK (GenomeWeb News) – Dako today said that it has signed an agreement with Bristol-Myers Squibb to develop pharmacogenomics tests to identify patients that are more likely to respond to drugs being developed by the drug firm.

The deal builds on a similar agreement between the firms reached in 2008. Terms of the newest agreement were not disclosed.

Dako specializes in tissue-based diagnostics, specifically for cancer.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.